

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Herl, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 12th February, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter ended 31.12.2021 and year to date from 01.04.2021 to 31.12. 2021

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter ended 31.12.2021 and year to date from 01.04.2021 to 31.12. 2021
2. Appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2021-22 as per the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto
3. Appointment of ANDROS & CO., Chartered Accountants with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2022-23 as per the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto
4. Revised Policy on Related Party Transactions

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 31.12.2021 and year to date from 01.04.2021 to 31.12.2021 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

1. Appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2021-22 as per the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto
2. Appointment of ANDROS & CO., Chartered Accountants with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2022-23 as per the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto
3. Revised Policy on Related Party Transactions

The above information will also be available on the Company's Website, www.genomicvalley.com.


The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 03:00 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Hanuman Prasad
Company Secretary & Compliance Officer
M.No.: 46027

GENOMIC VALLEY BIOTECH LIMITED
 Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
 TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
 CIN: L01122HR1994PLC033029

Statement of Un-Audited Financial Results for the quarter ended 31/12/2021 and Year to date from 01/04/2021 to 31/12/2021

In Rs.

Sr. No.	Particular	3 months ended		Preceding 3 months	Corresponding 3	Year to date	Year to date	Previous year ended
		31-Dec-21	30-Sep-21	ended	months ended in	figures for current	figures for	
		Un-Audited	Un-Audited		the previous year	period ended	previous period	
				31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21	
				Un-Audited	Un-Audited	Un-Audited	Audited	
I	Revenue From Operations	246,240	289,800		916,620	705,640	1,863,910	2,080,805
II	Other Income	784,548	-		-	784,548	-	29,221
III	Total Revenue (I+II)	1,030,788	289,800		916,620	1,490,188	1,863,910	2,110,026
IV	Expenses							
	Cost of materials consumed	15,410	4000		24,602	19,410	33,142	50,242
	Purchases of Stock-in-Trade	-	-		-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-		-	-	765,600	765,600
	Employee benefits expense	133,250	246,250		181,500	556,700	701,434	857,734
	Financial costs	-	-		-	426,203	-	1,774,570
	Depreciation and amortization expense	400,238	470,238		481,439	1,340,714	1,444,317	1,892,123
	Other expenses	373,393	140,967		365,342	698,074	674,184	1,787,900
	Total Expenses (IV)	922,291	861,455		1,052,883	3,041,101	3,618,677	7,128,169
V	Profit / (Loss) before exceptional item and tax (III-IV)	108,497	-571,655		-136,263	-1,550,913	-1,754,767	-5,018,143
VI	Exceptional Item	-	-		-	-	-	-
VII	Profit/loss before Tax (V-VI)	108,497	-571,655		-136,263	-1,550,913	-1,754,767	-5,018,143
VIII	Tax expenses							
	(1) Current Tax	-	-		-	-	-	-
	(2) Deferred Tax	-	-		-	-	-	572,371
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	108,497	-571,655		-136,263	-1,550,913	-1,754,767	-5,590,514
X	Profit/ (Loss) from discontinued operations	-	-		-	-	-	-
XI	Tax expense of discontinued operations	-	-		-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-		-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	108,497	-571,655		-136,263	-1,550,913	-1,754,767	-5,590,514
XIV	Other Comprehensive Income							
A	(i) Items that will not be reclassified to profit or loss	-	-		-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-		-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-		-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-		-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	108,497	-571,655		-136,263	-1,550,913	-1,754,767	-5,590,514
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500		3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):							
	1) Basic	0.04	-0.19		-0.04	-0.51	-0.57	-1.83
	2) Diluted	0.04	-0.19		-0.04	-0.51	-0.57	-1.83
XVIII	Earning Per Equity Share (for discontinued operation):							
	1) Basic	0.00	0.00		0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00		0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):							
	1) Basic	0.04	-0.19		-0.04	-0.51	-0.57	-1.83
	2) Diluted	0.04	-0.19		-0.04	-0.51	-0.57	-1.83

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 12th February, 2022. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



Yogesh Agrawal
 Yogesh Agrawal
 (Chairman & Managing Director)
 DIN-01165288
 Add: G-74 Pushkar Enclave
 Paschim Vihar, New Delhi-110063

Place: Delhi
 Dated: 12/02/2022

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended
December 31, 2021 and year to date from April 01, 2021 to December 31, 2021**

We have reviewed the accompanying statement of unaudited financial results for **the Quarter ended December 31, 2021 and year to date from April 01, 2021 to December 31, 2021** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For ANDROS & CO.
Chartered Accountants
FRN 008976N

Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi UDIN: 22502310-ABOVYK-1489
Date: 12-02-2022